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A B S T R A C T
The incidence of depression doubles in diabetic patients and is associated with poor outcomes. Studies indicate
that renin-angiotensin-aldosterone system inhibitors (RAASi) might relieve depression, however the mechanism
of action is not well understood. We recently showed that angiotensin receptor blockers have antidepressant
effects in experimental diabetes comorbid depression. Here we investigated whether all types of RAASi exhibit
antidepressant and neuroprotective properties. Diabetes was induced by streptozotocin in adult male Wistar rats.
After 5 weeks of diabetes, rats were treated per os with non-pressor doses of enalapril, ramipril, spironolactone or
eplerenone for 2 weeks. Behavior was evaluated using forced swim test and open field test. Inflammatory re-
sponse and brain-derived neurotrophic factor (BDNF) signaling were investigated in the hippocampus. Both
ACEi and MR antagonists reversed diabetes-induced behavioral despair confirming their antidepressant-like
effect. This may occur via alterations in hippocampal cytokine-mediated inflammatory response. Repressed
BDNF production was restored by RAASi. Both ACEi and MR antagonists facilitated the BDNF-tropomyosin
receptor kinase B-cAMP response element-binding protein signaling pathway as part of their neuroprotective
effect. These data highlight the important benefits of ACEi and MR antagonists in the treatment of diabetes-
associated depressive symptoms. Our novel findings support the link between diabetes comorbid depression,
inflammation and repressed BDNF signaling. RAASi could provide new therapeutic options to improve the
outcomes of both disorders.
1. Introduction
Diabetes and depression are vast challenges for modern healthcare
systems and generate a significant social and economic burden (Egede
et al., 2002; van Dieren et al., 2010). Diabetes is frequently associated
with depression leading to decreased quality of life and worse long-term
prognosis. The incidence of cognitive decline and depression is two to
three times higher in diabetic patients, however the majority of cases
remain under-diagnosed (Chen et al., 2016). On the other hand, de-
pression doubles the risk of developing diabetes (Rubin et al., 2008).
The pathophysiology between the two diseases remains elusive, even
though the bidirectional relationship seems to be certain (Renn et al.,
2011).
Mounting evidence point out the role of inflammation in the pa-
thophysiology of both diabetes and depression, which could be a
possible common mechanism of the two disorders (Stuart and Baune,
2012). Neuroinflammation and glial activation induce various patho-
logical changes that contribute to the onset of metabolic and neu-
ropsychiatric diseases. Inflammatory processes decrease brain-derived
neurotrophic factor (BDNF) production and interfere with tyrosine re-
ceptor kinase B (TrkB) signaling, which may impair synaptic plasticity
and neuronal survival (Tong et al., 2008, 2012).
BDNF is highly expressed in the central nervous system. It is syn-
thesized as a pre‐pro peptide, then converted to precursor form
(proBDNF) and finally proteolytically cleaved to mature BDNF
(mBDNF). It is now widely accepted that diminished BDNF signaling
through TrkB is associated with psychiatric disorders e.g. depression.
mBDNF mediates neuroplasticity processes such as neuronal survival,
neurogenesis and synaptic activity through TrkB (Atwal et al., 2000;
Rossi et al., 2006). Patients with depression have lower serum BDNF
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levels (Karege et al., 2002). In parallel, BDNF and TrkB expressions are
decreased in hippocampal samples of patients suffering from depression
(Pandey et al., 2008).
Renin-angiotensin-aldosterone system inhibitors (RAASi) are the
gold standard therapy of complications associated with diabetes
(Majewski and Bakris, 2016). To date, it has been confirmed that RAAS
is not only a circulating hormonal system. All elements of classic RAAS
are also expressed in the brain, where they regulate blood pressure,
cerebral circulation, central sympathetic activity, behavior and the
brain’s innate immune response (Paul et al., 2006; Saavedra, 2012).
Both systemic and local RAAS in the brain are over-activated in dia-
betes coupled with increased level of angiotensin II (Ang II) (Ribeiro-
Oliveira et al., 2008).
According to recent data, RAAS has also been implicated in the
pathomechanism of depression. A few clinical observations suggest a
connection between RAASi and reduced depressive symptoms, although
the underlying mechanisms are unclear (Ahola et al., 2014; Pavlatou
et al., 2008). Furthermore, case-control and cohort studies demonstrate
that patients taking RAASi have reduced risk of mood disorders
(Williams et al., 2016). Recently, our group showed that angiotensin
receptor blocker (ARB) losartan has an antidepressant effect in strep-
tozotocin-induced diabetic rats. Moreover, we reported that losartan
reduces neuroinflammation and facilitates the production and signaling
of the BDNF-TrkB-pathway, which might explain its neuroprotective
effect (Lenart et al., 2019).
Based on these findings here we investigated whether all types of
RAASi exhibit antidepressant and neuroprotective properties, focusing
on the potential role of BDNF signaling in particular. In a streptozo-
tocin-induced diabetes model angiotensin-converting enzyme inhibitors
(ACEi) enalapril or ramipril, and mineralocorticoid-receptor (MR) an-
tagonists spironolactone or eplerenone were applied to test their anti-
depressant-like effect and reveal their diverse mechanisms of action.
2. Experimental procedures
2.1. Study approval
All animal experiments and animal handling were conducted in
accordance with National Institutes of Health guidelines and
Committee on the Care and Use of Laboratory Animals of the Council on
Animal Care at the Semmelweis University of Budapest, Hungary (PEI/
001/1731-9-2015).
2.2. Materials
All chemicals and reagents were purchased from Sigma-Aldrich (St.
Louis, MO, USA) and all standard plastic laboratory equipment was
purchased from Sarstedt (Numbrecht, Germany) unless stated other-
wise.
2.3. Animals
Eight week-old male Wistar rats weighing 200± 10 g were pur-
chased from “Toxi-Coop” Toxicological Research Center (Dunakeszi,
Hungary). Rats were housed in groups of three with 12:12 h light-dark
cycle at room temperature (24± 2 °C) with ad libitum access to stan-
dard rodent chow and tap water.
2.4. Induction of diabetes and experimental design
Experiment 1: In a preliminary experiment, we tested the possible
effect of RAASi in healthy, non-diabetic rats. Therefore rats were ran-
domized into the following groups (n = 7 in control and n = 6 in
treatment groups) and treated for two weeks by oral gavage once daily
as follows: (I) isotonic saline as vehicle (C); (II) enalapril dissolved in
isotonic saline (C + ENA, 40 mg/bwkg/day); (III) ramipril dissolved in
isotonic saline (C + RAM, 10 μg/bwkg/day); (IV) spironolactone dis-
solved in isotonic saline (C + SPI, 50 mg/bwkg/day); (V) eplerenone
dissolved in isotonic saline (C + EPL, 50 mg/bwkg/day). RAASi doses
were adopted from our previous experiments in line with literary data
where effective blockade of ACE or aldosterone activity was reached
without changes in systemic blood pressure (Coppey et al., 2006; Grima
et al., 2001; Matsubara et al., 1999; Taira et al., 2008).
Experiment 2: Rats were intraperitoneally injected with streptozo-
tocin (STZ; 65 mg/bwkg) dissolved in 0.1 M citrate buffer (pH 4.5).
Blood glucose level was measured three times from tail vein with Dcont
Ideal device (77 Elektronika Kft., Budapest, Hungary) after overnight
fasting. Rats with a peripheral blood glucose value above 15 mmol/L 72
h after the STZ injection were enrolled in the study. Five weeks after the
onset of diabetes rats were randomized into five groups (n = 8 in
diabetic and n = 6 in treatment groups) and received RAASi treatment
as defined above. Age and body weight-matched non-diabetic control
rats (n = 8) received equivalent volumes of citrate buffer without STZ
once and the same amount of saline once daily as diabetic ones
throughout the 2-week treatment period.
At the end of the treatment period rats were anaesthetized (75 mg/
bwkg ketamine and 10 mg/bwkg xylazine mixture), sacrificed by ex-
sanguination, brains were harvested and immediately snap-frozen for
further investigation.
2.5. Behavior tests
Behavioral tests were performed after the oral gavage in a weakly
illuminated room (15 W). Rats were tested for locomotor activity by
open field test (OFT) three days before the end of the 7-week experi-
mental period. Depressive-like behavior was evaluated by forced swim
test (FST); the pre-test was conducted 24 h after the open field test
(OFT) and the test session was conducted 24 h after the pre-test. Rats
were sacrificed 24 h after the FST.
2.5.1. Open field test
OFT is performed to determine the general locomotor activity of rats
(Denenberg, 1969). In a large square chamber fenced by a plastic wall
(100 × 100 × 60 cm box) the arena floor was virtually divided into
equally sized 10 × 10 cm squares. Each rat was individually placed into
the center of the chamber and allowed to freely explore for the duration
of the test (10 min). When manually evaluating the OFT activity data,
we focused on the horizontal locomotor parameter (number of squares
crossed). The test was recorded and then analyzed by an observer blind
to the treatment protocol. The chamber was cleaned with water be-
tween the tests.
2.5.2. Forced swim test
The study was carried out on rats according to the method described
by Porsolt et al. FST is one of the most commonly used tests which is
sensitive to antidepressant-like effects. It is based on the assumption
that an animal will try to evade a stressful stimulus and it will first make
efforts to escape but eventually will exhibit immobility that can be
considered to reflect a measure of behavioral despair (Porsolt et al.,
1978, 1977). Rats were placed in a cylindrical container (60 cm tall, 14
cm in diameter) filled with tap water (25±1 °C). Water was changed
after each FST session. Rats were forced to swim for a 15 min pre-test
period. Twenty-four hours later, the procedure was repeated for a 5 min
FST session which was videotaped and later blindly scored by two
observers using a computer-assisted method. During the test session
time spent in mobility (struggling, swimming and diving) and im-
mobility were measured.
2.6. Measurement of arterial blood pressure and metabolic parameters
Arterial blood pressure (systolic, diastolic) was measured on tail
vein using a non-invasive CODA Standard monitor system (EMKA
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Technologies, Paris, France) which uses clinically validated proprietary
volume pressure recording. Mean arterial pressure (MAP) was calcu-
lated. Blood glucose, fructosamine, cholesterol, triglycerides, GOT and
GPT were photometrically measured from serum with generally avail-
able kits on a Hitachi 912 photometric chemistry analyzer (Roche
Hitachi, Basel, Switzerland).
2.7. Western blot
All reagents for Western blot were obtained from Bio-Rad
Laboratories Inc. (Hercules, CA, USA). Hippocampal samples were
homogenized, and protein concentration was measured. Sample lysates
of 40 μg/lane were electrophoretically resolved on 4–20 % poly-
acrylamide gels, transferred to nitrocellulose membranes and im-
munoblotted with the appropriate primary antibodies: phosphorylated
endothelial nitric oxide synthase (p-eNOS; Ser1177), phosphorylated
neuronal nitric oxide synthase nuclear (p-nNOS; Ser 852), endothelin-1,
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB),
BDNF, furin, matrix metalloproteinase-3 (MMP-3), p75 neurotrophin
receptor (p75NTR), phosphorylated c-Jun N-terminal kinase (p-JNK;
Thr183/Tyr185), TrkB, phosphorylated extracellular-signal-regulated
kinase (p-ERK; Tyr204), phosphorylated cAMP response element
binding protein (p-CREB; Ser133). Secondary antibodies were HRP-
conjugated for chemiluminescence detection by Luminata™ Forte
(Millipore Corporation, Billerica, MA, USA). Antibodies are listed in
supplementary data. Densitometric (Versadoc, Quantity One Analysis
software; Bio-Rad Laboratories, Hercules, CA, USA) analysis of bands of
interest was performed and background was subtracted from integrated
optical densities (IOD). IOD was factored for Ponceau S staining to
verify equal protein loading. Protein levels are represented as IOD /
Ponceau S / Inner control.
2.8. Quantitative RT-PCR
Total RNA was extracted using the Total RNA Mini Kit (Geneaid
Biotech Ltd, New Taipei City, Taiwan) and reverse-transcribed using
Maxima™ First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Fisher
Scientific, Waltham, MA, USA) to generate first-strand cDNA.
Interleukin-1α (Il1a), interleukin-6 (Il6), tumor necrosis factor-α (Tnf),
B-cell lymphoma 2 (Bcl2), Bcl-2-associated X protein (Bax) and 18S
ribosomal RNA (Rn18s) mRNA expressions were determined by real-
time quantitative RT-PCR using LightCycler 480 SYBR Green I Master
enzyme mix (Roche Diagnostics, Indianapolis, IN, USA) and specific
primers (primer sequences listed in Suppl. Table 1). Results were
evaluated by the LightCycler® 480 software version 1.5.0.39 (Roche
Diagnostics, Indianapolis, IN, USA). Results were normalized against
Rn18S expression as the housekeeping gene.
2.9. Statistical analysis
Before our experiments we performed a priori power analysis to
ascertain the required total sample size based on the predetermined α
= 0.05 significance level, β = 0.05 risk of type II error and the cal-
culated 1.01 effect size. Results are presented as means± SDs.
Statistical analysis was performed using Prism software (version 7.0;
GraphPad Software Inc., San Diego, CA, USA). Multiple comparisons
and interactions were evaluated by one-way analysis of variance
(ANOVA) followed by Holm-Sidak post hoc test. For non-parametrical
data the Kruskal-Wallis ANOVA on ranks followed by Dunn correction
was calculated. P values of< 0.05 were considered significant.
3. Results
Elevated serum glucose, fructosamine and lower body weight con-
firmed the development of diabetes. RAASi did not alter any of the
metabolic or somatic parameters (Suppl. Table 1).
3.1. RAASi alleviate the depressive-like behavior of diabetic rats
First, locomotor activity of control, diabetic and RAASi-treated
groups was investigated using OFT. The number of grid crossings of
both untreated and treated diabetic rats was lower than controls, sug-
gesting that their general physical condition was worse. RAASi treat-
ment did not improve the locomotor activity of diabetic rats.
Whether diabetes is associated with depressive behavior in our ex-
perimental model was investigated. During FST floating time was
longer, while mobility time was shorter in the diabetic group indicating
depressive-like behavior. Contrarily, RAASi decreased floating time and
simultaneously increased total time of mobility. When measuring var-
ious movement patterns (struggling, swimming, diving) separately, the
time spent struggling and swimming were lower in diabetic rats.
Struggling remained unchanged, while a slight increment was observed
in swimming after RAASi treatment, however the level of significance
was only reached in the case of ramipril (Table 1).
3.2. Behavioral tests of control and RAASi treated rats remained unaltered
Non-diabetic control rats also received RAASi treatment to in-
vestigate the direct effect of RAASi on behavior. Their performance did
not change significantly in the behavioral tests; therefore, we did not
Table 1
RAASi treatment ameliorates the depressive-like behavior of diabetic rats. Open field test (OFT) and forced swim test (FST) were performed on control, vehicle-
treated diabetic (D), enalapril (D + ENA) or ramipril (D + RAM) or spironolactone (D + SPI) or eplerenone (D + EPL) treated diabetic rats. During OFT, locomotor
activity was evaluated by measuring the number of grid crossings. In FST each moving pattern is represented as percentage of total test time. Floating time indicates
immobility, while active mobility consists of struggling, swimming and diving parameters. Data indicate means± SDs and were analyzed by one-way ANOVA with
Holm-Sidak multiple comparisons test or by Kruskal-Wallis test with Dunn correction. F values are results of Brown-Forsythe tests, followed by DFn and DFd numbers
(n = 8 in control and diabetic and n = 6 in treatment groups). *p< 0.05 vs. Control; **p< 0.01 vs. Control; ***p< 0.001 vs. Control; §p< 0.05 vs. Diabetic;
§§p<0.01 vs. Diabetic.
Behavioral test result Control Diabetic (D) D + ENA D + RAM D + SPI D + EPL p values F value
Number of grid crossings 364.5± 161.0 156.7± 127.5** 56.5± 28.5 166.2± 95.3 147.7± 37.0 158.3± 58.6 **p = 0.002 vs. Control 2.653 (5, 33)
Floating time (%) 19.2± 10.1 54.1± 12.2*** 36.4± 14.1§ 30.2± 12.6§§ 34.0± 18.2§ 37.8± 4.5§ ***p < 0.001 vs. Control 2.291 (5, 34)
§p< 0.026 vs. D
§§p = 0.005 vs. D
Mobility time (%) 80.8± 10.1 45.9± 12.2*** 63.7± 4.1§ 69.8± 12.6§§ 65.9± 18.2§ 62.2± 4.5§ ***p < 0.001 vs. Control 2.291 (5, 34)
§p< 0.026 vs. D
§§p = 0.005 vs. D
Struggling time (%) 31.2± 8.8 18.4± 2.1* 23.5± 5.3 23.8± 7.9 27.5± 16.2 25.1± 8.8 *p = 0.036 vs. Control 4.165 (5, 34)
Swimming time (%) 49.2± 9.9 27.1± 13.6** 39.0± 10.9 45.8± 13.4§ 36.7± 10.2 33.8± 7.1 **p = 0.002 vs. Control 0.333 (5, 34)
§p = 0.015 vs. D
Diving time (%) 0.4±0.5 0.4±0.6 1.1± 1.2 0.2± 0.3 0.9± 0.4 2.1± 0.7 §p = 0.034 vs. D 2.282 (5, 34)
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investigate the pathophysiological pathways in these animals (Table 2).
3.3. RAASi do not interfere with blood flow regulation in the diabetic brain
Next, the mechanisms through which RAASi may influence de-
pressive-like behavior were explored. Since MAP remained unaltered in
all groups (Fig. 1A), we hypothesized that the effects of RAASi are in-
dependent of systemic blood pressure regulation. The eNOS/nNOS
pathway and endothelin-1 are major regulators of cerebral blood flow
(CBF), however neither hippocampal p-eNOS and p-nNOS nor en-
dothelin-1 protein levels showed any alterations (Fig. 1B–D). This
suggests that the antidepressant actions of RAASi are independent of
cerebral vascular changes in this model.
3.4. RAASi mitigate diabetes-induced inflammation in the hippocampus
Inflammatory processes have been associated with both depression
and diabetes, therefore alterations of proinflammatory cytokine ex-
pressions were investigated. Elevated hippocampal protein level of the
main transcription factor NF-κB was decreased by RAASi (Fig. 1E). Il1a,
Il6 and Tnf mRNA were all increased in diabetic rats and were dimin-
ished by RAASi (Fig. 1F–H).
3.5. RAASi restore hippocampal BDNF production and transformation in
diabetes
BDNF and downstream signaling pathways play a pivotal role in the
pathophysiology of depression. Hippocampal synthesis of both
proBDNF and mBDNF decreased in diabetic rats. These changes were
fully reversed by RAASi treatment (Fig. 2A–B). While measuring clea-
vage enzymes responsible for BDNF transformation, we found that
different RAASi acted on different pathways. Interestingly enough, MR
antagonists increased the intracellular enzyme furin, while ACEi ele-
vated the extracellular MMP3 (Fig. 2C–D).
3.6. RAASi interact with hippocampal mature BDNF signaling
Precursor and mature BDNF forms bind to different receptors and
activate divergent pathways. ProBDNF acts on p75NTR and activates the
pro-apoptotic Bax transcription factor through phosphorylated JNK
mediator. The activation of this pathway leads to neuronal apoptosis
and decreased synaptic plasticity. However, in our model neither dia-
betes, nor RAASi induced any changes in this signaling cascade in the
hippocampus (Fig. 3A–C).
mBDNF binds to TrkB receptor after which the activated pathway
Table 2
Depressive-like behavior of control and RAASi treated rats are unaltered. Open field test (OFT) and forced swim test (FST) were performed were performed on
control (C), enalapril (C + ENA) or ramipril (C + RAM) or spironolactone (C + SPI) or eplerenone (C + EPL) treated control rats. During OFT, locomotor activity
was evaluated by measuring the number of grid crossings. In FST each moving pattern is represented as percentage of total test time. Floating time indicates
immobility, while active mobility consists of struggling, swimming and diving parameters. Data indicate means± SDs and were analyzed by one-way ANOVA with
Holm-Sidak multiple comparisons test or by Kruskal-Wallis test with Dunn correction. F values are results of Brown-Forsythe tests, followed by DFn and DFd numbers
(n = 7 in control and n = 6 in treatment groups).
Behavioral test result Control (C) C + ENA C + RAM C + SPI C + EPL p values F value
Number of grid crossings 336.1± 104.8 395.3± 123.9 368.3±65.4 410.3± 104.3 315.2± 144.9 Not significant 0.489 (4, 26)
Floating time (%) 38.8±10.4 30.9± 14.3 33.1± 14.6 38.9± 10.1 41.9±10.8 Not significant 0.339 (4, 26)
Mobility time (%) 61.2±10.4 69.1± 14.3 66.9± 14.6 61.0± 10.1 58.1±10.8 Not significant 0.339 (4, 26)
Struggling time (%) 29.3±7.9 27.9± 7.8 23.2± 7.4 22.7± 6.5 24.2±5.4 Not significant 0.362 (4, 26)
Swimming time (%) 31.4±5.0 41.1± 14.2 43.2± 13.2 37.5± 8.7 32.6±10.9 Not significant 1.413 (4, 26)
Diving time (%) 0.4± 0.5 0.2± 0.4 0.6± 0.3 1.5± 0.7 1.5± 0.6 Not significant 1.448 (4, 34)
Fig. 1. Regulation of cerebral perfusion is unaltered by RAASi, but they ameliorate proinflammatory responses in hippocampi of diabetic rats. (A) Mean
arterial pressure (MAP) was calculated in control, vehicle-treated diabetic (D), enalapril (D + ENA) or ramipril (D + RAM) or spironolactone (D + SPI) or
eplerenone (D + EPL) treated diabetic rats. (B–D) Fold changes of protein levels of blood flow regulating phosphorylated endothelial nitric oxide synthase (p-eNOS),
phosphorylated neuronal nitric oxide synthase (p-nNOS) and endothelin-1 were evaluated in hippocampi by Western blot. (E) Fold changes of protein levels of
proinflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). (F–H) Hippocampal mRNA expression of proinflammatory cytokine in-
terleukin-1α (Il1a), interleukin-6 (Il6) and tumor necrosis factor-α (Tnf) were measured by qRT-PCR. All proteins were normalized to total protein Ponceau S staining
as loading control. All mRNAs were normalized to Rn18SmRNA expression. Bars indicate means± SDs and data were analyzed by one-way ANOVA with Holm-Sidak
multiple comparisons test or by Kruskal-Wallis test with Dunn correction (n = 8 in control and diabetic and n = 6 in treatment groups). *p< 0.05 vs. Control;
**p<0.01 vs. Control; ***p< 0.001 vs. Control; §p<0.05 vs. Diabetic; §§p< 0.01 vs. Diabetic; §§§p<0.001 vs. Diabetic.
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phosphorylates extracellular ERK and CREB factors and leads to anti-
apoptotic Bcl-2 increment. TrkB, p-ERK, p-CREB protein levels and Bcl2
mRNA expression were decreased in the hippocampi of diabetic rats.
RAASi treatment reversed the decrement in all cases (Fig. 3D–G).
4. Discussion
The possible association between diabetes and depression was re-
cognized as early as the 17th century, however it has only been in-
tensively studied in the last decade. RAASi are the cornerstones of the
Fig. 2. Hippocampal BDNF production is
increased by RAASi in diabetic rats. (A–D)
Fold changes of protein levels of precursor
brain-derived neurotrophic factor (BDNF),
mature BDNF (mBDNF) and its cleavage en-
zymes furin and matrix metalloproteinase-3
(MMP3) were evaluated in hippocampi by
Western blot in control, vehicle-treated dia-
betic (D), enalapril (D + ENA) or ramipril (D
+ RAM) or spironolactone (D + SPI) or
eplerenone (D + EPL) treated diabetic rats. All
proteins were normalized to total protein
Ponceau S staining as loading control. Bars
indicate means± SDs and data were an alyzed
by one-way ANOVA with Holm-Sidak multiple
comparisons test or by Kruskal-Wallis test with
Dunn correction (n = 8 in control and diabetic
and n = 6 in treatment groups). *p< 0.05 vs.
Control; ***p<0.001 vs. Control; §p<0.05
vs. Diabetic; §§p< 0.01 vs. Diabetic;
§§§p<0.001 vs. Diabetic.
Fig. 3. Neuronal response in diabetes can be altered by RAASi via mBDNF-TrkB signaling in the hippocampus. (A–B) Fold changes of protein levels in
proBDNF pathway: p75 neurotrophin receptor (p75NTR) and phosphorylated c-Jun N-terminal kinase (p-JNK) were evaluated in hippocampi by Western blot; (C)
Hippocampal mRNA expression of pro-apoptotic Bcl-2-associated X protein (Bax) was measured by qRT-PCR in control, vehicle-treated diabetic (D), enalapril (D +
ENA) or ramipril (D + RAM) or spironolactone (D+ SPI) or eplerenone (D+ EPL) treated diabetic rats. (D–F) Fold changes of protein levels in downstream elements
of mBDNF pathway: tropomyosin receptor kinase B (TrkB), phosphorylated extracellular-signal-regulated kinase (p-ERK) and phosphorylated cAMP response ele-
ment binding protein (p-CREB) were measured in hippocampi by Western blot. (G) Hippocampal mRNA expression of pro-survival B-cell lymphoma 2 (Bcl2) was
measured by qRT-PCR. All proteins were normalized to total protein Ponceau S staining as loading control. All mRNAs were normalized to Rn18S mRNA expression.
Bars indicate means± SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test or by Kruskal-Wallis test with Dunn correction (n
= 8 in control and diabetic and n = 6 in treatment groups). *p<0.05 vs. Control; **p<0.01 vs. Control; §p< 0.05 vs. Diabetic; §§p< 0.01 vs. Diabetic;
§§§p< 0.001 vs. Diabetic.
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management of diabetes-related complications. All components of
RAAS have been identified in the brain and are suggested to be involved
in the pathomechanism of depression. The first evidence that RAAS in
the brain is involved in depression was observed in hypertensive pa-
tients who showed reduced depressive symptoms after receiving ACEi
(Germain and Chouinard, 1988, 1989). Recently, our group reported
that losartan minimizes depressive-like behavior via modulating the
BDNF pathway in diabetic rats, independently of serum glucose and
blood pressure. To investigate whether all types of RAASi exhibit these
beneficial effects, here we tested the efficacy of enalapril, ramipril,
spironolactone or eplerenone treatment in diabetes-associated depres-
sion.
The main finding of the present study is that ACEi and MR an-
tagonists have antidepressant-like effect in diabetic rats, which is
characterized by decreased total immobility (floating) time in FST.
Immobility reflects behavioral despair and it is the most relevant
parameter in the characterization of depression-like behavior. Others
showed that ACEi reduce depression-like behavior in healthy animals
subjected to FST (Giardina and Ebert, 1989; Nayak and Patil, 2008).
Further, spironolactone has been reported to decrease immobility time
in FST in a corticosterone-induced depression model (Wu et al., 2013).
Beside immobility, active parameters (swimming or struggling) reflect
escape-seeking behavior and have been shown to be relevant as well. A
paper reported that increased time of swimming is connected to the
activation of serotonergic system, while longer struggling is associated
with increased catacholaminergic neurotransmission (Cryan et al.,
2005). The time of swimming was increased significantly only by ra-
mipril, while struggling remained unaltered in all RAASi-treated
groups. Further, locomotion was not affected by RAASi confirming that
the results are independent of the rats' physical condition.
The ‘vascular depression hypothesis’ highlights the link between
cerebral vascular disease and depression. Diabetes-related changes in
cerebral hemodynamics contribute to the development of depression.
Reduced eNOS levels (Demir et al., 2015; Utkan et al., 2015), elevated
endothelin-1 and activation of RAAS resulted in detrimental vascular
alterations and local vasoconstriction in the diabetic brain (Saavedra,
2005). Here, the eNOS/nNOS pathway and endothelin-1 were not al-
tered significantly in the hippocampus in all groups. This was not un-
expected in light of our recent in vivo SPECT-CT measurements showing
that losartan did not improve decreased CBF (Lenart et al., 2019). These
results together with unchanged MAP indicate that the beneficial an-
tidepressant-like effect of ACEi and MR antagonist are not due to a
vasoactive action.
Inflammation has been implicated in the pathophysiology of both
depression and diabetes, which may be one link between the two dis-
eases (Leonard and Maes, 2012; Shoelson et al., 2006). Overactivation
of RAAS has been identified in diabetes and neuropsychiatric disorders
(e.g. Alzheimer’s disease, depression), which are frequently associated
with neurodegeneration and neuroinflammation (Gebre et al., 2018;
Vargas et al., 2012; Yagi et al., 2013). The activation of local brain
RAAS is characterized by elevated ACE expression, AngII generation
and AT1R expression (Gong et al., 2019). Cerebral Ang II induces mi-
croglial activation and release of proinflammatory cytokines. Data
concerning the role of mineralocorticoids in depression-associated in-
flammation is limited, but aldosterone has been demonstrated to in-
crease proinflammatory cytokine levels in the brain (Dinh et al., 2016).
In our model hippocampal elevation of Il1a, Il6 and Tnf indicate the
activation of the NF-κB-mediated inflammatory pathway in diabetes-
associated depression, similarly to models of other psychiatric disorders
(Asraf et al., 2018; Dinh et al., 2016; Torika et al., 2016). Furthermore,
we showed that both ACEi and MR antagonists mitigate inflammatory
response. Together with our previous results, these findings support the
anti-inflammatory role of RAASi as a novel mechanism of action in
diabetes comorbid depression.
Neuroinflammation interacts with neurotransmitter metabolism,
neuroendocrine function, synaptic plasticity and alters behavior. IL-1,
IL-6 and TNF have profound stimulatory effects on hypothalamic-pi-
tuitary-adrenal axis and contribute to changes in neuronal growth and
survival (Silverman et al., 2005). Studies demonstrated that adminis-
tration of IL-1 decreases the neurotrophin BDNF in rat hippocampus
(Lapchak et al., 1993; Zhang et al., 2014) leading to cognitive dys-
function. Earlier we reported that hippocampal BDNF is reduced in
diabetes-associated depression (Lenart et al., 2016) and the alteration is
reversed by losartan (Lenart et al., 2019). Here we showed that not only
ARBs, but also ACEi and MR antagonists suspend BDNF decrement.
These data provide novel evidence of the link between diabetes-induced
neuroinflammation and BDNF abatement.
BDNF is initially synthesized as pre-pro-BDNF, then the pre-region is
removed yielding the pro-BDNF. The N-terminal region is proteolyti-
cally cleaved by intracellular furin and/or extracellular matrix me-
talloproteases (MMPs) to produce the mature form (Lu et al., 2005).
Here we found that ACEi and MR antagonists act on different proteo-
lytic cleavage pathways. ACEi elevated extracellular MMP3, while the
intracellular enzyme furin was increased by MR antagonists. Interest-
ingly enough, according to our previous paper ARBs exert their effect
on both. These cleavage enzymes may be targets of RAASi and might
suggest a possible synergistic antidepressant performance of combina-
tion therapy.
Identifying molecular pathways by which altered BDNF signaling
could lead to depression in diabetes is of paramount importance. Lu
et al. propose a ‘yin and yang’ model of neurotrophin action, since
BDNF forms have opposing effects on cell survival. Hippocampal
p75NTR activated JNK-Bax signaling leads to neuronal apoptosis, while
the TrkB-ERK-CREB pathway mediates cell survival and has a crucial
role in antidepressant effects (Chen et al., 2001). Here, the pro-apop-
totic pathway remained unchanged, while the pro-survival pathway
was impaired. We demonstrated that TrkB and its downstream ele-
ments, p-ERK and p-CREB were repressed in the diabetic hippocampus.
This is in line with our previous results and other studies showing im-
peded hippocampal BDNF signaling in diabetes (Agrawal et al., 2014;
Lenart et al., 2019; Qin et al., 2016). Both ACEi and MR antagonists
increased TrkB, p-ERK and p-CREB levels. CREB-dependent transcrip-
tional mechanism activates Bcl-2, which possesses anti-apoptotic effects
and enhances neuronal survival (Riccio et al., 1999). In accordance
with this, here we showed that Bcl2 expression was higher in diabetic
rats treated with ACEi or MR antagonists. These results suggest that
activated BDNF-mediated pro-survival pathway contributes to hippo-
campal plasticity and thus moderates depressive-like behavior.
In conclusion, the present study provides experimental data for the
antidepressant-like effect of RAASi in diabetes comorbid depression.
We hypothesize that diabetes-induced neuroinflammation decreases
BDNF level, which contributes to neuronal damage and subsequently to
the development of depression-like behavior. Our results indicate that
both ACEi and MR antagonists reduce neuroinflammation and promote
BDNF maturation resulting in the activation of BDNF-mediated pro-
survival pathway. According to this, we propose two additional possible
mechanisms by which RAASi may exert neuroprotection and anti-
depressant-like action. Ultimately, various RAASi may provide a novel
therapeutic opportunity to treat and improve outcomes of both dis-
orders simultaneously.
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